Personalized medicine in sarcoidosis: predict responders and nonresponders

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33154233" target="_blank" >RIV/61989592:15110/15:33154233 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1097/MCP.0000000000000194" target="_blank" >http://dx.doi.org/10.1097/MCP.0000000000000194</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MCP.0000000000000194" target="_blank" >10.1097/MCP.0000000000000194</a>

Result language
angličtina
Original language name
Personalized medicine in sarcoidosis: predict responders and nonresponders
Original language description
PURPOSE OF REVIEW: Treatment of sarcoidosis, a granulomatous disease affecting multiple organs with predominance to the lung, is complicated by variable response of individual patients to treatment options ranging from corticosteroids to second-line steroid-sparing agents and further to biologicals. This is partially because of varying disease manifestation, but polymorphic genes affecting drug metabolization substantially contribute. This review deals with pharmacogenetic (PGx) factors underlying interindividual differences of treatment response in sarcoidosis regarding personalized approach to patient management. RECENT FINDINGS: No firm evidence is available for introducing genotyping metabolizing enzymes and/or transporters (Cytochrome P450, TPMT,ABCB1 and so on) despite drugs they target (azathioprine and methotrexate) are used in sarcoidosis. Variation in TNFA gene, which was associated with response to tumor necrosis factor inhibitors (infliximab and adalimumab), is in line wit
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)